Acumen Pharmaceuticals Inc (ABOS)

Dec 04, 2025

Can Acumen Pharmaceuticals Inc. stock hit analyst price targetsJuly 2025 WrapUp & AI Powered Buy/Sell Recommendations - Newser

Dec 04, 2025

Dec 03, 2025

Acumen presents new research on Alzheimer’s treatment delivery By Investing.com - Investing.com Canada

Dec 03, 2025

Dec 03, 2025

Acumen Pharmaceuticals (ABOS) Stock Analysis Report | Financials & Insights - Benzinga

Dec 03, 2025

Dec 03, 2025

Is Acumen Pharmaceuticals Inc. stock a dividend growth opportunityOil Prices & Short-Term High Return Ideas - Newser

Dec 03, 2025

Dec 02, 2025

Acumen Pharmaceuticals Presents Results on Alzheimer’s Disease at Conference - Yahoo

Dec 02, 2025

Dec 02, 2025

Acumen and JCR Advance Next-Generation CNS Therapeutics with EBD™ Technology - citybiz

Dec 02, 2025

Dec 02, 2025

What analysts say about Acumen Pharmaceuticals Inc stockStock Liquidity Analysis & Invest Like A Pro - earlytimes.in

Dec 02, 2025

Dec 02, 2025

Acumen Pharmaceuticals highlights enhanced brain delivery technology for oligomer-selective antibodies - marketscreener.com

Dec 02, 2025

Dec 02, 2025

Acumen (NASDAQ: ABOS) reports CTAD results on 15 to 68-fold delivery and ALTITUDE-AD recruitment - Stock Titan

Dec 02, 2025

Nov 28, 2025

Acumen Pharmaceuticals And 2 Other Penny Stocks Worth Watching - Yahoo Finance

Nov 28, 2025

Nov 27, 2025

Wall Street analysts’ outlook for Acumen Pharmaceuticals Inc (ABOS) - Setenews

Nov 27, 2025

Nov 27, 2025

Is Acumen Pharmaceuticals Inc. stock supported by innovation pipeline2025 Breakouts & Breakdowns & Consistent Growth Equity Picks - moha.gov.vn

Nov 27, 2025

Nov 25, 2025

Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Receives $6.75 Average Target Price from Analysts - Defense World

Nov 25, 2025

Nov 24, 2025

Is Acumen Pharmaceuticals Inc a good long term investmentTrade Execution Strategies & Big Profit Small Investment - earlytimes.in

Nov 24, 2025

Nov 21, 2025

Published on: 2025-11-21 08:02:34 - newser.com

Nov 21, 2025

Nov 20, 2025

Will Acumen Pharmaceuticals Inc. stock go up soonTrade Risk Assessment & Capital Efficiency Focused Ideas - newser.com

Nov 20, 2025

Nov 20, 2025

Why Acumen Pharmaceuticals Inc. stock is favored by top institutionsWeekly Trade Summary & Free AI Powered Buy and Sell Recommendations - newser.com

Nov 20, 2025

Nov 20, 2025

Using data models to predict Acumen Pharmaceuticals Inc. stock movementQuarterly Profit Report & Expert Approved Momentum Ideas - newser.com

Nov 20, 2025

Nov 20, 2025

How risky is Acumen Pharmaceuticals Inc. stock nowJuly 2025 Catalysts & Risk Controlled Stock Pick Alerts - newser.com

Nov 20, 2025

Nov 19, 2025

Is Acumen Pharmaceuticals Inc. stock dividend yield sustainableQuarterly Profit Summary & Verified Entry Point Signals - newser.com

Nov 19, 2025

Nov 19, 2025

Acumen Pharmaceuticals (ABOS) Price Target Decreased by 20.59% to 6.88 - MSN

Nov 19, 2025

Nov 19, 2025

Can Acumen Pharmaceuticals Inc. rally from current levelsTrade Performance Summary & Fast Exit and Entry Strategy Plans - newser.com

Nov 19, 2025

Nov 19, 2025

Is Acumen Pharmaceuticals Inc. stock recession proofJuly 2025 Retail & Daily Oversold Bounce Ideas - newser.com

Nov 19, 2025

Nov 19, 2025

Reversal indicators forming on Acumen Pharmaceuticals Inc. stockJuly 2025 News Drivers & Entry and Exit Point Strategies - newser.com

Nov 19, 2025

Nov 19, 2025

Is Acumen Pharmaceuticals Inc. stock attractive for passive investorsQuarterly Trade Summary & Daily Technical Stock Forecast Reports - newser.com

Nov 19, 2025

Nov 18, 2025

B of A Securities Maintains Acumen Pharmaceuticals (ABOS) Buy Recommendation - Nasdaq

Nov 18, 2025

Nov 18, 2025

ABOS: B of A Securities Lowers Price Target But Maintains Buy Ra - GuruFocus

Nov 18, 2025

Nov 18, 2025

Acumen Pharmaceuticals to Present on Recruitment Strategies for Phase 2 ALTITUDE-AD Trial and Enhanced Brain Delivery Technology at 18th Annual Clinical Trials on Alzheimer’s Disease (CTAD) Conference - The Manila Times

Nov 18, 2025

Nov 18, 2025

SR Bancorp (NASDAQ: SRBK) announces $0.05 dividend payable Oct. 15 - Stock Titan

Nov 18, 2025

Nov 18, 2025

Acumen Pharmaceuticals begins open-label extension for Alzheimer’s drug By Investing.com - Investing.com Canada

Nov 18, 2025

Nov 17, 2025

How to forecast Acumen Pharmaceuticals Inc. trends using time seriesJuly 2025 Breakouts & Reliable Volume Spike Alerts - newser.com

Nov 17, 2025

Nov 17, 2025

Acumen stock maintains Buy rating at Stifel ahead of late-2026 readout - Investing.com UK

Nov 17, 2025

Nov 17, 2025

Acumen Pharmaceuticals Reports Q3 2025 Financial Results - MSN

Nov 17, 2025

Nov 17, 2025

Acumen Pharmaceuticals Announces First Participant Dosed in Phase 2 Open-Label Extension Study of Sabirnetug in People with Early Alzheimer’s Disease - The Manila Times

Nov 17, 2025

Nov 17, 2025

Acumen Pharmaceuticals begins open-label extension for Alzheimer’s drug - Investing.com India

Nov 17, 2025

Nov 17, 2025

Acumen Pharmaceuticals (NASDAQ: ABOS) doses first patient in Phase 2, 52-week OLE - Stock Titan

Nov 17, 2025

Nov 16, 2025

Will a bounce in Acumen Pharmaceuticals Inc. offer an exitJobs Report & Expert Curated Trade Setups - newser.com

Nov 16, 2025

Nov 15, 2025

Tools to monitor Acumen Pharmaceuticals Inc. recovery probabilityMarket Growth Review & Fast Exit and Entry Trade Guides - newser.com

Nov 15, 2025